PRE Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 1.65
- P/S (TTM)
- 3.11
- EV/EBITDA
- 0.14
Profitability & growth
- ROE (TTM)
- -31.8%
- Operating margin
- -33.3%
- Revenue growth YoY
- 248.6%
- Dividend yield
- —
- Beta
- 0.15
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Prenetics Global Ltd
Company profilePrenetics Global Ltd (PRE) is a premier health technology innovator focused on delivering advanced genetic and diagnostic testing solutions that empower consumers and healthcare professionals with critical health insights. With a diverse portfolio of state-of-the-art testing services and integrated digital health offerings, the company has seen significant international growth, fueled by strategic partnerships and a strong commitment to ongoing research and development. As a frontrunner in the personalized medicine space, Prenetics is ideally positioned to capitalize on the increasing demand…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- UNIT 703-706, K11 ATELIER KING?S ROAD, QUARRY BAY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer